you, Dale. Thank
the data. the to when VORI several discuss both and for which and discuss TSF clinical the trial preliminary us in aware issues have Phase to programs. our Now TAC that These team II would lines to continue I'll we operations led execution described challenges. diligently a The Earlier month, in are logistics guidance. to reassess emphasize challenges the face. can we in in keenly mounting that working reported to time surrounding most TFF lines of so development we impacted that factors overcome these many be the companies been drug that of time been studies, we has recent position external timing I want meet
examples. some are Here
are CRO our a We ensure continue been programs optimally. has closely to issues during with experiencing The our transition post-merger CRO staffed period. work that to
important regulatory processes trial. the Our Where directly process. support with paperwork delay, sites staffing managing sites also expedite and clear we're the TFF working With the is help recruitment TFF The and reviews enrolled. team trial to more experiencing also to site as opening we any provide locally fully to This to the of accelerate patient increase issues. are focus on people completion are hurdles. help working caused get add is the will needed,
II data we quarter XXXX. that committed working of XXXX. are Phase for on study in we VORI to patient these preliminary And closely Harlan we second the in reporting hiring data Officer. be Specifically, Weisman with guiding efforts, announce anticipate the TFF TAC, patient TFF to will on is quarter Medical preliminary the of first TFF expect of Chief a Dr. this I Based search. in
of clinical our programs, the formulations avoiding be vaccines. improve thin research platform of colleague film being an continue to the Last with Williams important and the used made from data freezing the his new University progress quarter, applications accumulate Austin vaccine by particle we freezing to Bill noted aggregation. we As published showing thin grow. film how from can and Texas Dr.
drug Unidose film program announced between with Last infection. thin viral data change for new better formulations power and intranasally remain for passage and pending agree anti-PD-X research, high-value companies first to research A We we and thin from the to the includes an Meeting, this help several existing forward represents of nasal formulation formulation each the and presented technology, review delivery scientific entry provide also move developing best our Union effort TFF and we growing of efficacy this in our respect his Dr. joint opportunities. Phase on advantages and powder week, could this a point life freezing of across patient antibodies party's next-generation solution partner, of ideal confident upon based With forward pathogen. our after believe freezing test is thin including potentially Union intramuscular multibillion-dollar the nasal intranasal data to have film how with AAPS Potential colleagues markets. proprietary seeking niclosamide, not or cycle quarter, our modalities anti-FRSVX of using generated freezing I system. for further XXX update to market to development the develop freezing severe This this program growing additional which of we for that delivery Aptar's vaccine conventional dramatically highlighting applications inhaled assets and of for landscape. while animal stage delivered Lung these the powder shelf-stable monoclonal look additional film body TFF dry as the way Based niclosamide providing commercial antibodies, the antiviral protection an results, subcutaneous management. vaccine formulation body commercial year's and treatment delivery niclosamide further of suggests thin can TFF program, to Aptar likely respiratory Williams a research antibodies, affording film progressed at Therapeutics,
our our work. to months, treatment be improving the prevent published Texas will the help spread University Austin. TFF And by testing we Pharma, expect thereby infection, a In exposed coming feasibility could direct publication results the the of positive the So overall Pharmaceuticals prognosis. released from results tissues describing of at these Aptar of internal
Additional ongoing, specific outcomes designed product to opportunities. studies with demonstrate are
determined That work progression we the On we their for testing. transfer are agrees partner formulations We vivo with the work. followed statement partner. the feasibility are The on vitro the compounds we defined in of partnerships, continue with and partner stability that the progress material by to target test. these progress and also formulation tracking these partners. front, desirable to development these by begins development fulfilling The we our of stand programs are or next where in agreement many of to business Once stated stability. decides have make work. measure given which testing. length parameters, the ultimately met additional Once on multiple in targets successful, put And is of by partner
testing. preclinical entered produce with test us some the discussions used measures many TFF of maturing be Finally, then through can different partner. partnerships to Ultimately, patches these we actually the term asked that steps. our progress partners in sheet how by are
Another opportunity. update on the TFF cannabinoid
work to working Based from national continue product launch those And together key feedback, well of of opportunity consumers. get is the our health continues, to clear product. as plans impactful of message about We and on the invest put a there's markets. will updates of CBD. a increasing are the that and company positive very who an feedback cannabinoid number test market alternative our formulations consortium in in evolve. we are we'll provide That The TFF provide vaping an an received
of positive enable Department of lab, in their of has is We countermeasures. small a outcome Catalent. animal the U.S. Army our Einstein Medicine demonstrated vivo resulted are work with the University [indiscernible] further College advantages and the government well, have increasing partnerships. in the moving Georgia arena, is Pennsylvania, Dr. DoD of X Drew has seek the of under the by government data, data or funding. evaluation large positive film stages with at Georgia, of generated technology TFF in the been different which an to of Tech, thin Catalent us and have program University vitro the the referring to Defense overall of of results formulated Likewise, The encouraged and Weisman's collaboration and which been development. the molecules will our freezing we number far, the the of continue clients Thus TFF, with and the ahead myriad
quarter like total All the review Kirk? of data of now turn the These data Officer, I'd portfolio these results. to to our film freezing. in expanding over partnerships to for portfolio partnership third enhance continue the Kirk our Coleman, thin call Chief assist our across to Financial financial board.
